Ascendis Pharma A/S (NASDAQ:ASND) Given Outperform Rating at Royal Bank Of Canada

Royal Bank Of Canada reiterated their outperform rating on shares of Ascendis Pharma A/S (NASDAQ:ASND) in a research note issued to investors on Friday morning,Benzinga reports. They currently have a $290.00 price objective on the biotechnology company’s stock.

Other analysts have also issued research reports about the company. Wall Street Zen upgraded Ascendis Pharma A/S from a “hold” rating to a “buy” rating in a research note on Sunday, November 8th. BMO Capital Markets reissued an “outperform” rating on shares of Ascendis Pharma A/S in a research note on Thursday, September 10th. Stifel Nicolaus lowered their target price on shares of Ascendis Pharma A/S from $328.00 to $326.00 and set a “buy” rating for the company in a research note on Monday, August 31st. Canaccord Genuity Group upped their price target on shares of Ascendis Pharma A/S from $268.00 to $274.00 and gave the stock a “hold” rating in a report on Friday. Finally, Citigroup reduced their price target on shares of Ascendis Pharma A/S from $360.00 to $330.00 and set a “buy” rating on the stock in a research note on Monday, October 26th. Nineteen equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat, Ascendis Pharma A/S currently has a consensus rating of “Moderate Buy” and an average target price of $313.52.

Ascendis Pharma A/S Trading Up 3.1%

ASND opened at $275.39 on Friday. The company has a debt-to-equity ratio of 0.27, a quick ratio of 2.32 and a current ratio of 2.99. The stock’s 50 day moving average price is $242.67 and its 200-day moving average price is $239.83. Ascendis Pharma A/S has a one year low of $188.08 and a one year high of $282.15. The stock has a market cap of $17.18 billion, a price-to-earnings ratio of 18.00 and a beta of 0.40.

Ascendis Pharma A/S (NASDAQ:ASND) last issued its quarterly earnings results on Friday, August 14th. The biotechnology company reported $1.03 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.71 by ($0.68). Ascendis Pharma A/S had a return on equity of 44.80% and a net margin of 73.26%. The business had revenue of $387.22 million for the quarter, compared to the consensus estimate of $376.75 million. On average, equities analysts forecast that Ascendis Pharma A/S will post 3.43 EPS for the current year.

Insider Transactions at Ascendis Pharma A/S

In related news, SVP Mads Bodenhoff sold 3,000 shares of the stock in a transaction that occurred on Tuesday, September 8th. The stock was sold at an average price of $270.19, for a total value of $810,570.00. Following the transaction, the senior vice president owned 3,000 shares of the company’s stock, valued at $810,570. This represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 40.00% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Ascendis Pharma A/S

A number of institutional investors and hedge funds have recently bought and sold shares of ASND. Perceptive Advisors LLC lifted its holdings in shares of Ascendis Pharma A/S by 41.6% in the 1st quarter. Perceptive Advisors LLC now owns 1,531,421 shares of the biotechnology company’s stock worth $350,282,000 after buying an additional 450,000 shares during the period. Sei Investments Co. grew its position in shares of Ascendis Pharma A/S by 24.8% during the 1st quarter. Sei Investments Co. now owns 351,146 shares of the biotechnology company’s stock worth $80,318,000 after buying an additional 69,673 shares in the last quarter. Allspring Global Investments Holdings LLC increased its stake in shares of Ascendis Pharma A/S by 27.0% during the third quarter. Allspring Global Investments Holdings LLC now owns 227,013 shares of the biotechnology company’s stock valued at $51,602,000 after buying an additional 48,275 shares during the period. Frazier Life Sciences Management L.P. increased its stake in shares of Ascendis Pharma A/S by 68.9% during the second quarter. Frazier Life Sciences Management L.P. now owns 225,155 shares of the biotechnology company’s stock valued at $60,053,000 after buying an additional 91,822 shares during the period. Finally, Empowered Funds LLC increased its stake in shares of Ascendis Pharma A/S by 0.5% during the third quarter. Empowered Funds LLC now owns 188,229 shares of the biotechnology company’s stock valued at $42,884,000 after buying an additional 958 shares during the period.

Latest Ascendis Pharma A/S News

These are some of the ASND news items that stood out recently:

• Positive Sentiment: Pipeline and cash-flow updates add support. European regulators issued positive opinions for TransCon CNP, with a final European Commission decision expected in Q4 2026. Management expects at least €600 million in full-year operating cash flow. Read More.
• Neutral Sentiment: Analyst views are not unanimous. Canaccord raised its target to $274 but kept a hold rating, while HC Wainwright cut its target to $335, though it retained a buy rating. Read More. · Read More.
• Negative Sentiment: Employee warrants may cause modest dilution. Ascendis granted 28,030 employee warrants, creating a potential increase in shares outstanding if exercised. Read More.

About Ascendis Pharma A/S

Ascendis Pharma A/S is a biopharmaceutical company headquartered in Denmark that develops medicines for rare diseases, with a focus on endocrinology. Founded in 2006, the company uses its TransCon technology platform to design therapies intended to provide sustained delivery of medicines. Its commercial products include SKYTROFA (lonapegsomatropin), a once-weekly growth hormone treatment for children with growth hormone deficiency, and YORVIPATH (palopegteriparatide), a treatment for adults with hypoparathyroidism.